4th Annual RAS Targeted Drug Development Summit
Evvnt Promotion / evvnt
Archiv
26.09.2022 - 28.09.2022 Boston Marriott Burlington, One Burlington Mall Road, 01803 Burlington, Massachusetts, USA
Time: 8:30 AM - 6:00 PM
Kongressthemen
For decades, RAS has existed as an elusive therapeutic target, and drugging this high-value oncogene was deemed impossible. Despite this, the first-ever FDA-approved KRAS G12C inhibitor has demonstrated that RAS is in fact druggable and that drugging this protein unlocks a world of successful therapeutic interventions. Now, the future looks bright for treating patients with cancers harboring the RAS mutation.
For decades, RAS has existed as an elusive therapeutic target, and drugging this high-value oncogene was deemed impossible. Despite this, the first-ever FDA-approved KRAS G12C inhibitor has demonstrated that RAS is in fact druggable and that drugging this protein unlocks a world of successful therapeutic interventions. Now, the future looks bright for treating patients with cancers harboring the RAS mutation.
Kongressorganizer (PCO)
Hanson Wade
Hanson Wade
Anfragen und Anmeldung:
https://go.evvnt.com/1209735-2?pid=4832
Frau Erin Thomas
Allgemeinmedizin
Sprache
Englisch
Englisch
Kongressgebühr
USD 2599.00 - USD 5398.00
USD 2599.00 - USD 5398.00
Teilnehmer erwartet
1000
1000
Veranstalter Kontakt
83 Great Titchfield Street
W1W 6RH London
Großbritannien
83 Great Titchfield Street
W1W 6RH London
Großbritannien
"GOING INTERNATIONAL fördert den Zugang zu Aus-, Fort- und Weiterbildung, unabhängig von sozialen, geographischen und nationalen Grenzen."
